Investegate announcements from AstraZeneca PLC, Ultomiris approved in Japan for gMG

Related Keywords

Japan , Taiwan , United States , United Kingdom , Massachusetts , Boston , China , Cambridge , Cambridgeshire , America , Japanese , Marc Dunoyer , Hiroyuki Murai , Adrian Kemp , School Of Medicine , National Organization For Rare Disorders , Department Of Neurology , International University Of Health , Alexion Pharmaceuticals Inc , Nasdaq , Astrazeneca , Japanese Ministry Of Health , Investor Relations Team , European Union , National Institutes Of Neurological Disorders , Devices Agency , Japan Pharmaceuticals , York Academy Of Sciences , Medical Devices Agency , Japanese Ministry , Myasthenia Gravis Activities , Daily Living Profile , International University , Chief Executive Officer , Neurology Annual Meeting , North America , Myasthenia Gravis Foundation , America Clinical Classification Class , Astrazeneca Rare Disease , Alexion Pharmaceuticals , Rare Diseases , New York Academy , Nationwide Population Based Epidemiological Study , Myasthenia Gravis , Ocular Myasthenia Gravis , National Organization , Rare Disorders , Accessed March , Clinical Overview , Gravis Fact , National Institutes , Neurological Disorders , Efficacy Study , Adults With Generalized Myasthenia , Investegate Announcements , Investegate Company Announcements , Astrazeneca Plc , Egulatory News Service , Egulatory News Service And Regulatory , Ns ,